MCID: SCN036
MIFTS: 52

Secondary Progressive Multiple Sclerosis

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 51 14
Multiple Sclerosis, Secondary Progressive 69
Multiple Sclerosis, Chronic Progressive 41
Chronic Progressive Multiple Sclerosis 28
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 41 D020528
SNOMED-CT 64 425500002
UMLS 69 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to meningitis and multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dimethyl fumarate and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and cortex, and related phenotypes are cellular and hematopoietic system

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 meningitis 30.0 CD40LG IL10 MMP9
2 multiple sclerosis 29.5 CCR5 CXCL10 CXCR3 IFNB1 IL10 IL4
3 relapsing-remitting multiple sclerosis 29.3 IFNB1 IL10 IL4 MBP MMP9
4 auditory system cancer 10.5 ENO2 MMP9
5 lentigo maligna melanoma 10.5 MMP9 S100B
6 intracranial cysts 10.5 ENO2 S100B
7 acute transverse myelitis 10.5 IL10 MMP9
8 bednar tumor 10.5 ENO2 S100B
9 finger agnosia 10.5 ENO2 MBP
10 ross river fever 10.5 CD40LG IL10
11 epithelioid malignant peripheral nerve sheath tumor 10.5 ENO2 S100B
12 neonatal hypoxic and ischemic brain injury 10.5 ENO2 MBP
13 ossifying fibromyxoid tumor 10.5 ENO2 S100B
14 retroperitoneal neuroblastoma 10.5 ENO2 IFNB1
15 meningovascular neurosyphilis 10.4 CD40LG MBP
16 folliculotropic mycosis fungoides 10.4 CCR3 CXCR3
17 post-vaccinal encephalitis 10.4 CD40LG MBP
18 zika fever 10.4 CD40LG IFNB1
19 tropical spastic paraparesis 10.4 CXCR3 IL10 MMP9
20 bronchiolitis obliterans 10.4 CXCR3 IL10 MMP9
21 head injury 10.4 ENO2 S100B
22 sporotrichosis 10.4 CD40LG IL10
23 appendicitis 10.4 ENO2 IL10 MMP9
24 balo concentric sclerosis 10.4 IFNB1 MBP
25 transverse myelitis 10.4 IL10 MBP MMP9
26 necrotizing ulcerative gingivitis 10.4 CD40LG IL10
27 opsoclonus-myoclonus syndrome 10.4 CXCL10 CXCR3
28 bacterial meningitis 10.4 IL10 MMP9 S100B
29 allergic encephalomyelitis 10.4 CXCL10 MBP
30 cow milk allergy 10.4 CCR5 IL10
31 mucocutaneous leishmaniasis 10.3 CCR5 IL10
32 optic nerve glioma 10.3 ENO2 MBP S100B
33 dysgammaglobulinemia 10.3 CD40LG MBP
34 cerebral primitive neuroectodermal tumor 10.3 ENO2 IFNB1 S100B
35 middle cerebral artery infarction 10.3 CD40LG ENO2 S100B
36 tropical endomyocardial fibrosis 10.3 IL10 IL4
37 pineocytoma 10.3 ENO2 S100B
38 hyperlucent lung 10.3 IL10 IL4
39 viral encephalitis 10.2 CXCL10 IL10 MBP
40 tungiasis 10.2 IL10 IL4
41 endomyocardial fibrosis 10.2 IL10 IL4
42 acute disseminated encephalomyelitis 10.2 IL10 MBP
43 tick-borne encephalitis 10.2 CCR5 CXCL10 IL10
44 lymphoproliferative syndrome 2 10.2 CD40LG CXCL10 CXCR3
45 retinitis pigmentosa 22 10.2 IL10 IL4
46 japanese spotted fever 10.2 CD40LG CXCL10
47 baylisascariasis 10.2 IL10 IL4
48 traumatic brain injury 10.2 ENO2 IL10 MBP S100B
49 chromoblastomycosis 10.2 CXCR3 IL4 MMP9
50 brain injury 10.2 ENO2 IL10 MBP S100B

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 IL4 CXCL10 CCR2 CXCR3 ENO2 CCR3
2 hematopoietic system MP:0005397 10.18 IL4 CXCL10 CCR2 CXCR3 CCR3 IFNB1
3 homeostasis/metabolism MP:0005376 10.18 CXCL10 CCR2 CXCR3 CCR3 IFNB1 CCR5
4 immune system MP:0005387 10.1 IL4 CXCL10 CCR2 CXCR3 CCR3 IFNB1
5 nervous system MP:0003631 9.85 CXCL10 CCR2 ENO2 IFNB1 CCR5 IL10
6 neoplasm MP:0002006 9.73 CCR2 CXCR3 IFNB1 CCR5 IL10 MMP9
7 no phenotypic analysis MP:0003012 9.43 CCR2 IFNB1 CCR5 IL10 IL4 RORC
8 respiratory system MP:0005388 9.17 CCR2 CXCR3 ENO2 CCR3 IL10 IL4

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
2
Interferon beta-1a Approved, Investigational Phase 4,Phase 2 145258-61-3 6438354
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
4
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6 Dermatologic Agents Phase 4,Phase 3,Phase 1
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
8 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Interferon-beta Phase 4,Phase 3,Phase 2
12 interferons Phase 4,Phase 3,Phase 2
13 Potassium Channel Blockers Phase 4,Phase 3
14 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
15 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
16 glucocorticoids Phase 4,Phase 3,Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
21
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 3,Phase 1 50-24-8 5755
23
Simvastatin Approved Phase 3,Phase 2 79902-63-9 54454
24
Natalizumab Approved, Investigational Phase 3,Phase 2,Phase 1 189261-10-7
25
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
27 Alkylating Agents Phase 3
28 Antiemetics Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 3,Phase 1,Phase 2
30 Autonomic Agents Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
32 Methylprednisolone acetate Phase 3,Phase 1
33 Methylprednisolone Hemisuccinate Phase 3,Phase 1
34 Neuroprotective Agents Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
36 Prednisolone acetate Phase 3,Phase 1
37 Prednisolone hemisuccinate Phase 3,Phase 1
38 Prednisolone phosphate Phase 3,Phase 1
39 Protective Agents Phase 3,Phase 2,Phase 1
40 Antioxidants Phase 2, Phase 3,Phase 1
41 Micronutrients Phase 2, Phase 3,Phase 1
42 Thioctic Acid Phase 2, Phase 3,Phase 1
43 Trace Elements Phase 2, Phase 3,Phase 1
44 Vitamin B Complex Phase 2, Phase 3,Phase 1
45 Vitamins Phase 2, Phase 3,Phase 1
46 Anticholesteremic Agents Phase 3,Phase 2
47 Antimetabolites Phase 3,Phase 2,Phase 1
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3,Phase 2
49 Hypolipidemic Agents Phase 3,Phase 2,Phase 1
50 Lipid Regulating Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 69)

# Name Status NCT ID Phase Drugs
1 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
2 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS Completed NCT00463710 Phase 4 Avonex® monotherapy (6.0 MIU administered i.m. each week)
3 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
4 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Recruiting NCT03269175 Phase 4
5 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4 Fampridine;Placebo
6 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
7 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
8 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
9 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
10 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
11 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3 masitinib;placebo
12 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
13 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
14 Multiple Sclerosis-Simvastatin Trial 2 Not yet recruiting NCT03387670 Phase 3 Simvastatin;Placebo
15 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
16 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
17 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
18 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
19 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
20 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
21 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
22 Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Completed NCT02228213 Phase 2 Saline
23 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
24 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
25 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2 masitinib;masitinib
26 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
27 Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Completed NCT01056471 Phase 1, Phase 2
28 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
29 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
30 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
31 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo
32 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
33 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
34 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed NCT00436826 Phase 2 Cladribine;Placebo;Interferon-beta (IFN-beta)
35 Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Recruiting NCT02308137 Phase 2 Domperidone
36 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Recruiting NCT02649985 Phase 1, Phase 2 [F-18]PBR06
37 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting NCT01466114 Phase 2 estriol;Norethindrone
38 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
39 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Active, not recruiting NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
40 Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Active, not recruiting NCT02495766 Phase 1, Phase 2 XCEL-MC-ALPHA;Placebo
41 Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) Terminated NCT01212094 Phase 1, Phase 2 Rituximab
42 Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT01181089 Phase 1, Phase 2
43 Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01381354 Phase 1
44 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Completed NCT00559702 Phase 1 natalizumab
45 A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Completed NCT02253264 Phase 1 Rituximab
46 Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Completed NCT00813969 Phase 1
47 Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis Completed NCT00997438 Phase 1
48 Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis Recruiting NCT01647321 Phase 1
49 Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients Recruiting NCT03282760 Phase 1
50 Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis Recruiting NCT03283826 Phase 1 ATA188

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Genetic tests related to Secondary Progressive Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Chronic Progressive Multiple Sclerosis 28

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

38
Brain, B Cells, Cortex, T Cells, Thyroid, Myeloid

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 111)
# Title Authors Year
1
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. ( 28770099 )
2018
2
Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. ( 28145395 )
2017
3
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. ( 28801580 )
2017
4
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis. ( 29128442 )
2017
5
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. ( 28572730 )
2017
6
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. ( 28594298 )
2017
7
Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. ( 28838904 )
2017
8
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. ( 28429241 )
2017
9
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study. ( 29177070 )
2017
10
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. ( 28045953 )
2017
11
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort. ( 29111873 )
2017
12
Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis. ( 28521618 )
2017
13
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? ( 27753181 )
2017
14
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. ( 28600189 )
2017
15
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. ( 29138536 )
2017
16
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. ( 28905255 )
2017
17
Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. ( 28601572 )
2017
18
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. ( 28396953 )
2017
19
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis. ( 27408797 )
2016
20
Correction to: The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 27032440 )
2016
21
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. ( 27003945 )
2016
22
Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce. ( 27229156 )
2016
23
RORI^t Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis. ( 27413074 )
2016
24
HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. ( 27917400 )
2016
25
White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. ( 26733423 )
2016
26
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. ( 27685028 )
2016
27
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. ( 27620894 )
2016
28
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. ( 27430119 )
2016
29
iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. ( 27965675 )
2016
30
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. ( 26943957 )
2016
31
The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 26692498 )
2016
32
Secondary Progressive Multiple Sclerosis: Definition and Measurement. ( 27166830 )
2016
33
Defining secondary progressive multiple sclerosis. ( 27401521 )
2016
34
Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. ( 27570566 )
2016
35
Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients. ( 27919195 )
2016
36
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. ( 27996064 )
2016
37
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. ( 26788129 )
2016
38
The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis. ( 27513853 )
2016
39
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. ( 27739247 )
2016
40
The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. ( 27507559 )
2016
41
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. ( 27803641 )
2016
42
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. ( 26943959 )
2016
43
Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis. ( 27339072 )
2016
44
Expression of DNA methylation genes in secondary progressive multiple sclerosis. ( 26711572 )
2016
45
Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study. ( 27636543 )
2016
46
Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial. ( 26566454 )
2015
47
'You are just left to get on with it': qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. ( 26201723 )
2015
48
Beta-interferon exposure and onset of secondary progressive multiple sclerosis. ( 25846809 )
2015
49
Cortical sources of resting state electroencephalographic rhythms differ in relapsing-remitting and secondary progressive multiple sclerosis. ( 26111485 )
2015
50
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36. ( 26533994 )
2015

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
2 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
3 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh37 Chromosome 12, 54677685: 54677685

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 CCR2 CCR5 CD40LG CXCL10 IFNB1 IL10
2
Show member pathways
13.69 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
3
Show member pathways
13.47 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
4
Show member pathways
13.2 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
5
Show member pathways
13.03 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
6
Show member pathways
13.02 CCR2 CCR5 CD40LG CXCL10 IFNB1 IL10
7
Show member pathways
12.76 CCR2 CCR3 CCR5 CXCL10 CXCR3
8 12.45 CCR2 CD40LG CXCL10 IL10 IL4
9
Show member pathways
12.44 CCR3 CCR5 IFNB1 MMP9
10
Show member pathways
12.31 CCR5 CD40LG IL10 IL4
11
Show member pathways
12.22 CXCL10 IL4 MMP9 RORC
12
Show member pathways
12.14 CCR5 CD40LG IL10 IL4
13
Show member pathways
12.02 IFNB1 IL10 IL4
14
Show member pathways
12.01 CCR2 CCR3 CCR5 CXCL10 CXCR3 MMP9
15 11.87 CCR3 IL10 IL4
16 11.85 IL10 IL4 MMP9 RORC
17 11.76 CCR2 CCR5 IFNB1 IL10
18 11.63 CCR2 CXCL10 IL4 MBP MMP9
19 11.61 CXCR3 IL10 IL4 RORC
20 11.59 CD40LG IL10 IL4
21 11.55 CD40LG IL10 IL4
22 11.42 CCR2 CCR3 IL4 MMP9
23
Show member pathways
11.42 CCR2 CCR3 CCR5 CXCL10 CXCR3
24 11.21 CCR2 CD40LG MMP9
25 11.16 IFNB1 IL10 IL4
26 11.09 CD40LG CXCL10 IL10 IL4
27 10.71 CCR2 CCR5 CXCL10 IL10 IL4

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CD40LG CXCL10 ENO2 IFNB1 IL10 IL4
2 neuronal cell body GO:0043025 9.46 CCR2 ENO2 MBP S100B
3 external side of plasma membrane GO:0009897 9.02 CCR2 CCR5 CD40LG CXCL10 CXCR3

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.88 CD40LG CXCL10 IFNB1 IL10 IL4
2 cell surface receptor signaling pathway GO:0007166 9.84 CCR5 CXCL10 CXCR3 IFNB1
3 immune response GO:0006955 9.8 CCR2 CCR5 CD40LG CXCL10 IL10 IL4
4 defense response GO:0006952 9.76 CCR5 CXCL10 IFNB1
5 cellular response to lipopolysaccharide GO:0071222 9.75 CCR5 CXCL10 IL10
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.73 CCR2 CCR3 CCR5 CXCR3
7 inflammatory response GO:0006954 9.7 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
8 B cell differentiation GO:0030183 9.67 CD40LG IFNB1 IL10 IL4
9 cellular defense response GO:0006968 9.62 CCR2 CCR3 CCR5 IL4
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.59 IL10 MMP9
11 B cell proliferation GO:0042100 9.58 CD40LG IFNB1 IL10
12 positive regulation of monocyte chemotaxis GO:0090026 9.57 CCR2 CXCL10
13 dendritic cell chemotaxis GO:0002407 9.56 CCR2 CCR5
14 T cell chemotaxis GO:0010818 9.55 CXCL10 CXCR3
15 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.52 IL10 MBP
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.51 IL10 IL4
17 type 2 immune response GO:0042092 9.49 IL10 IL4
18 regulation of isotype switching GO:0045191 9.46 IL10 IL4
19 chemokine-mediated signaling pathway GO:0070098 9.35 CCR2 CCR3 CCR5 CXCL10 CXCR3
20 chemotaxis GO:0006935 9.1 CCR2 CCR3 CCR5 CXCL10 CXCR3 IL4

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 CD40LG CXCL10 IFNB1 IL10 IL4
2 C-C chemokine binding GO:0019957 9.26 CCR3 CCR5
3 C-C chemokine receptor activity GO:0016493 9.13 CCR2 CCR3 CCR5
4 chemokine receptor activity GO:0004950 8.92 CCR2 CCR3 CCR5 CXCR3

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....